Intelligence Feed event · Equity · 2026-10-01

    Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in Nature

    Question

    Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in Nature

    Direct answer

    Theriva Biologics published comprehensive findings from its randomized Phase 2b VIRAGE clinical trial in Nature Medicine. The trial assessed systemic administration of VCN-01 (zabilugene almadenorepvec) in combination with standard chemotherapy against first-line metastatic pancreatic ductal adenocarcinoma. The published data confirmed statistically significant enhancements across overall survival (OS), progression-free survival (PFS), and duration of response relative to standard-of-care chemotherapy alone.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in Nature”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-reports-positive-phase-2b-pancreatic-cancer-data-in-nature-e4c379

    EQUITY
    Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in Nature
    Theriva Biologics published comprehensive findings from its randomized Phase 2b VIRAGE clinical trial in Nature Medicine. The trial assessed systemic administration of VCN-01 (zabilugene almadenorepvec) in combination with standard chemotherapy against first-line metastatic pancreatic ductal adenocarcinoma. The published data confirmed statistically significant enhancements across overall survival (OS), progression-free survival (PFS), and duration of response relative to standard-of-care chemotherapy alone.
    TOVX
    Impact
    68
    OCT 1
    SIG
    82%
    TOVX
    Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in Nature
    Theriva Biologics published comprehensive findings from its randomized Phase 2b VIRAGE clinical trial in Nature Medicine. The trial assessed systemic administration of VCN-01 (zabilugene almadenorepvec) in combination with standard chemotherapy against first-line metastatic pancreatic ductal adenocarcinoma. The published data confirmed statistically significant enhancements across overall survival (OS), progression-free survival (PFS), and duration of response relative to standard-of-care chemotherapy alone.
    → Peer-reviewed Phase 2b clinical validation in Nature Medicine increases licensing and partnership feasibility for TOVX oncology pipeline assets.
    Impact
    Theriva Biologics published comprehensive findings from its randomized Phase 2b VIRAGE clinical trial in Nature Medicine. The trial assessed systemic administration of VCN-01 (zabilugene almadenorepvec) in combination with standard chemotherapy against first-line metastatic pancreatic ductal adenocarcinoma. The published data confirmed statistically significant enhancements across overall survival (OS), progression-free survival (PFS), and duration of response relative to standard-of-care chemotherapy alone.
    Affected
    TOVX
    Transmission
    Peer-reviewed Phase 2b clinical validation in Nature Medicine increases licensing and partnership feasibility for TOVX oncology pipeline assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXclinical pipeline validation and future partner licensing optionalityUp1-5dNature Medicine published Phase 2b survival improvements for VCN-01 in metastatic pancreatic cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month